The current trading session witnesses a significant surge in the value of Annovis Bio, Inc. (NYSE: ANVS) stocks. At present, Annovis shares display a notable increase of 38.26%, reaching $6.06 on the charts of the US stock exchange. This upturn in ANVS share price follows the release of updated clinical trial data.
Today, Annovis Bio (ANVS) has disclosed the successful completion of data refinement for its phase II/III investigation of buntanetap in individuals with mild to moderate Alzheimer’s disease (AD). The release of primary efficacy data is anticipated in April.
Buntanetap (previously recognized as Posiphen or ANVS401) combats neurodegeneration by impeding the generation of various neurotoxic proteins, including amyloid beta, tau, alpha synuclein, and TDP43, thus ameliorating synaptic transmission, axonal transport, and neuroinflammation.
Dysregulation within these pathways has been identified as the primary cause of neuronal degeneration and eventual demise. By targeting these pathways, buntanetap possesses the potential to reverse neurodegeneration in Alzheimer’s disease.
Annovis reveals that the company has transitioned from data refinement to the organization and statistical analysis of data for its Alzheimer’s study, which concluded in February. The swift completion of data refinement represents a commendable feat. The ANVS team has exerted considerable effort to furnish reliable data, and anticipation is high for the release of primary results next month.
The phase II/III AD study was conducted as a randomized, double-blind, placebo-controlled trial aimed at assessing the efficacy, safety, and tolerability of buntanetap in individuals with mild to moderate AD. Over 700 patients were screened, and 353 of them were enrolled and 327 of them completed the study.
As the company gears up to unveil the primary efficacy data next month, the collective anticipation within the scientific community and financial markets underscores the pivotal role of Annovis Bio in shaping the future landscape of Alzheimer’s research and therapeutic interventions.
